Oral: Xatral® OD
Indicated for benign prostatic hypertrophy
Sanofi-Synthelabo’s multi-dose formulation
Sold in more than 80 countries worldwide
European sales of US$100m
Launched in 10 European countries
France, UK, Netherlands, Switzerland, Sweden, Italy
Fastest conversion of multi to single dose formulation in UK
“Approvable letter” received from US FDA - Oct 2001
Additional clinical data available before end of 2002